Abstract
A review is presented of the use of porcine factor VIII (F.VIII) in patients with F.VIII inhibitors and acquired or congenital hemophilia. This review is drawn partly from the published literature and partly from an international survey of the use of porcine F.VIII in patients with congenital hemophilia conducted under the auspices of the ISTH F.VIII and IX scientific standardization subcommittee. The treatment of congenital and acquired hemophilia are compared, since they differ in a number of important respects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kernoff PBA, Thomas ND, Iilley PA, Clinical experience with polyelectrolytefractionated porcine FVIII concentrate in the treatment of haemophiliacs with antibodies to factor VIIL Blood 1984, 63; 31 – 41.
Gatti L, Mannucci PM, Use of porcine factor VIII in the management of seventeen patients with FVIII antibodies. Thrombosis and Haemostasis 1984, 51; 379 – 392.
Brettler DB, Forsberg A, Levine PH, et al.. The use of porcine factor VIILC in the treatment of patients with inhibitor antibodies to VIILC: A multicenter US trial. Arch intern Med 1989, 149; 1381 – 1385.
Morrison AE, Ludlam CA, Kessler C, Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993, 81; (6): 1513–1520.
Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982, 60; 1103 – 9.
Lozier JN, Santagostino E, Kasper CK, Teitel JM, Hay CRM, The use of porcine factor VIII for surgical procedures in haemophilia A patients with inhibitors. Seminars in Hematology, 1993, 30; (2): supp 1; 10–21.
Hay CRM, Laurian Y, Verroust F, Preston FE, Kernoff PBA, Induction of immune tolerance in patients with haemophilia A and inhibitors treated with porcine factor VIIIC by home therapy. Blood 1990, 76; 882 – 886.
Gringeri A, Santagostino E, Tradati F, Giangrande PLF, Mannucci PM, Adverse effects of treatment with porcine factor VIIL Thrombosis and Haemostasis 1991, 65; 245 – 247.
. Kernoff PBA, The factor Vlll-related antigen and antibodies to factor VIII. MD Thesis, University of London 1974.
Altieri DC, Capitanio AM, Mannucci PM, Von Willebrand factor contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation. Brit J Haematol 1986, 63, 703 – 711.
Fukui H, Yoshioka A, Shima M, Mori K, Yorifuji H, et al. Multicenter clinical trial of a highly purified porcine factor VIII concentrate (MTI-9002 (Hyate.C)) in haemophilia A patients with inhibitors. Japanese J Thrombosis and Haemostasis 1991,2; (6): 487–50.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Plenum Press, New York
About this chapter
Cite this chapter
Hay, C., Lozier, J.N. (1995). Porcine factor VIII therapy in patients with factor VIII inhibitors. In: Aledort, L.M., Hoyer, L.W., Lusher, J.M., Reisner, H.M., White, G.C. (eds) Inhibitors to Coagulation Factors. Advances in Experimental Medicine and Biology, vol 386. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0331-2_12
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0331-2_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-8001-6
Online ISBN: 978-1-4613-0331-2
eBook Packages: Springer Book Archive